The FDA has authorised two artificial formulations of THC for dealing with distinct problems: nabilone and dronabinol.THC targets receptors in a way significantly less selective than endocannabinoid molecules, and its pharmacodynamic tolerance might limit maximal consequences of specific medicines whilst enhancing the drug's therapeutic window.Whet